Stockreport

Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Clearmind Medicine Inc. - Common Shares  (CMND) 
PDF This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 20 [Read more]